TY - JOUR
T1 - Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis
AU - Maiga, Mariama C.
AU - Ahidjo, Bintou Ahmadou
AU - Maiga, Mamoudou
AU - Bishai, William R.
N1 - Publisher Copyright:
© 2015, American Society for Microbiology. All Rights Reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
AB - With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
UR - http://www.scopus.com/inward/record.url?scp=84954570108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954570108&partnerID=8YFLogxK
U2 - 10.1128/AAC.02145-15
DO - 10.1128/AAC.02145-15
M3 - Article
C2 - 26438491
AN - SCOPUS:84954570108
SN - 0066-4804
VL - 59
SP - 7888
EP - 7890
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 12
ER -